Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.
暂无分享,去创建一个
Hairong Zhou | J. Ohren | L. Royer | Kimberly A Stevens | C. Kane | A. Casimiro-Garcia | C. Bigge | JoAnn Davis | Teresa Padalino | J. Pulaski | P. McConnell | B. Auerbach | W. Collard | C. McGregor | S. Fakhoury | Wendy T Collard | Christopher F Bigge | Agustin Casimiro-Garcia | Robert P Schaum | Jeffrey F Ohren | Jo Ann Davis | Teresa Padalino | James Pulaski | Patrick McConnell | Christopher D Kane | Lori J Royer | Bruce J Auerbach | Christine McGregor | Stephen A Fakhoury | Hairong Zhou | Kimberly A. Stevens | R. Schaum
[1] J. Lehmann,et al. The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .
[2] G. Ortar,et al. An Improved Preparation of 4-Hydroxymethyl-L-Phenylalanine , 1998 .
[3] A. R. Miller,et al. Investigational PPAR-γ agonists for the treatment of Type 2 diabetes , 2006 .
[4] A. Vagin,et al. MOLREP: an Automated Program for Molecular Replacement , 1997 .
[5] Andrew C. Li,et al. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. , 2006, Annual review of pharmacology and toxicology.
[6] C. Saudek. Progress and promise of diabetes research. , 2002, JAMA.
[7] S. Gaetani,et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.
[8] K. Moulder,et al. Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.
[9] R. Babine,et al. Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis. , 2004, Bioorganic & medicinal chemistry letters.
[10] Millard H. Lambert,et al. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .
[11] J. Lehmann,et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. , 1998, Journal of medicinal chemistry.
[12] T. Hoye,et al. Amidoacetone enolate anions: alkylation and Michael reaction , 1985 .
[13] L. Ellinger,et al. 62. A new route to iminazoles: synthesis of 2-ω-aminoalkyl derivatives of 4-methyliminazole , 1949 .
[14] J. Lehmann,et al. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. , 1999, Journal of medicinal chemistry.
[15] H. Miyachi,et al. Molecular Modeling Study of Species-Selective Peroxisome Proliferator-Activated Receptor (PPAR) α Agonist; Possible Mechanism(s) of Human PPARα Selectivity of an α-Substituted Phenylpropanoic Acid Derivative (KCL) , 2004 .
[16] B. Lohray,et al. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. , 2001, Journal of medicinal chemistry.
[17] B. Ljung,et al. AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200127-JLR200 , 2002, Journal of Lipid Research.
[18] J. B. Hendrickson,et al. Triflamides: new acylating and triflating reagents , 1973 .
[19] M. Macías-González,et al. Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation. , 2007, Journal of medicinal chemistry.
[20] Robert M. Sweet,et al. Macromolecular Crystallography: Part A , 1997 .
[21] L. Moore,et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Fleckner,et al. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. , 2003, Journal of medicinal chemistry.
[23] J. Berger,et al. The mechanisms of action of PPARs. , 2002, Annual review of medicine.
[24] B. Henke. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. , 2004, Journal of medicinal chemistry.
[25] J. Clark,et al. The Diabetic Zucker Fatty Rat , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[26] M. Srebnik,et al. Hydroboration of Alkynes with Pinacolborane Catalyzed by HZrCp2Cl , 1995 .
[27] N. Blomberg,et al. Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .
[28] P. Cheng,et al. PPARs as targets for metabolic and cardiovascular diseases. , 2005, Mini reviews in medicinal chemistry.
[29] J. Lehmann,et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.
[30] A. Mittal,et al. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. , 2006, Mini reviews in medicinal chemistry.
[31] H. Miyachi,et al. Analysis of the Critical Structural Determinant(s) of Species-Selective Peroxisome Proliferator-Activated Receptor Alpha (PPARα)-Activation by Phenylpropanoic Acid-Type PPARα Agonists , 2003 .
[32] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[33] J. Chiasson,et al. Prevention of type 2 diabetes: insulin resistance and beta-cell function. , 2004, Diabetes.
[34] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[35] Weiqi Wang,et al. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. , 2005, Journal of medicinal chemistry.
[36] P. Charifson,et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. , 1998, Journal of medicinal chemistry.
[37] Margaret S. Wu,et al. A Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis , 2004 .
[38] Bruno Derudas,et al. Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.
[39] E. Gulve,et al. Chemistry and biochemistry of type 2 diabetes. , 2004, Chemical reviews.
[40] Masahiro Suzuki,et al. Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators. , 2003, Journal of medicinal chemistry.
[41] K. Sonogashira,et al. Development of Pd–Cu catalyzed cross-coupling of terminal acetylenes with sp2-carbon halides , 2002 .
[42] W. Wahli,et al. PPARα Structure-Function Relationships Derived from Species-Specific Differences in Responsiveness to Hypolipidemic Agents , 1997, Biological chemistry.
[43] B. Hulin,et al. Hypoglycemic Activity of a Series of α-Alkylthio and α-Alkoxy Carboxylic Acids Related to Ciglitazone , 1996 .
[44] B. Matthews,et al. Determination of molecular weight from protein crystals. , 1974, Journal of molecular biology.
[45] G. Crisp,et al. Palladium-catalysed attachment of labels with acetylenic linker arms to biological molecules , 1997 .
[46] G. Stephenson,et al. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. , 2004, Journal of medicinal chemistry.
[47] Norio Miyaura,et al. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds , 1995 .
[48] T. Willson,et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.
[49] J. Tilley,et al. Preparation of carboalkoxyalkylphenylalanine derivatives from tyrosine , 1990 .
[50] G. Cooney,et al. Peroxisome Proliferator—Activated Receptor (PPAR)-α Activation Lowers Muscle Lipids and Improves Insulin Sensitivity in High Fat—Fed Rats Comparison With PPAR-γ Activation , 2001 .
[51] Jay S Skyler,et al. Diabetes mellitus: pathogenesis and treatment strategies. , 2004, Journal of medicinal chemistry.
[52] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[53] K. Watson,et al. Atherosclerosis in Type 2 Diabetes Mellitus: The Role of Insulin Resistance , 2003, Journal of cardiovascular pharmacology and therapeutics.
[54] F. Diederich,et al. Book review: Metal-catalyzed cross-coupling reactions. F. Diederich and P. J. Stang (eds) Wiley–VCH, Weinheim, 1998. xxi + 517 pages, £85 ISBN 3–527–29421–X , 1998 .
[55] S. Kahn,et al. Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.
[56] T. Willson,et al. Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. , 2001, Bioorganic & medicinal chemistry letters.
[57] M. Kobayashi,et al. Improvement of Glucose Tolerance in NIDDM by Clofibrate Randomized Double-Blind Study , 1988, Diabetes Care.